Your browser doesn't support javascript.
loading
Disease pathology signatures in a mouse model of Mucopolysaccharidosis type IIIB.
Petrova, Ralitsa; Patil, Abhijeet R; Trinh, Vivian; McElroy, Kathryn E; Bhakta, Minoti; Tien, Jason; Wilson, David S; Warren, Liling; Stratton, Jennifer R.
Affiliation
  • Petrova R; Biologics Discovery Science, Teva Pharmaceutical Industries Ltd, Redwood City, CA, USA. ralitsaip@gmail.com.
  • Patil AR; Genomics and Computational Biology, Teva Pharmaceutical Industries Ltd, West Chester, PA, USA.
  • Trinh V; Biologics Discovery Science, Teva Pharmaceutical Industries Ltd, Redwood City, CA, USA.
  • McElroy KE; Biologics Discovery Science, Teva Pharmaceutical Industries Ltd, Redwood City, CA, USA.
  • Bhakta M; Biologics Discovery Science, Teva Pharmaceutical Industries Ltd, Redwood City, CA, USA.
  • Tien J; Biologics Discovery Science, Teva Pharmaceutical Industries Ltd, Redwood City, CA, USA.
  • Wilson DS; Biologics Discovery Science, Teva Pharmaceutical Industries Ltd, Redwood City, CA, USA.
  • Warren L; Genomics and Computational Biology, Teva Pharmaceutical Industries Ltd, West Chester, PA, USA.
  • Stratton JR; Biologics Discovery Science, Teva Pharmaceutical Industries Ltd, Redwood City, CA, USA. Jennifer.Stratton@tevapharm.com.
Sci Rep ; 13(1): 16699, 2023 10 04.
Article in En | MEDLINE | ID: mdl-37794029
ABSTRACT
Mucopolysaccharidosis type IIIB (MPS IIIB) is a rare and devastating childhood-onset lysosomal storage disease caused by complete loss of function of the lysosomal hydrolase α-N-acetylglucosaminidase. The lack of functional enzyme in MPS IIIB patients leads to the progressive accumulation of heparan sulfate throughout the body and triggers a cascade of neuroinflammatory and other biochemical processes ultimately resulting in severe mental impairment and early death in adolescence or young adulthood. The low prevalence and severity of the disease has necessitated the use of animal models to improve our knowledge of the pathophysiology and for the development of therapeutic treatments. In this study, we took a systematic approach to characterizing a classical mouse model of MPS IIIB. Using a series of histological, biochemical, proteomic and behavioral assays, we tested MPS IIIB mice at two stages during the pre-symptomatic and early symptomatic phases of disease development, in order to validate previously described phenotypes, explore new mechanisms of disease pathology and uncover biomarkers for MPS IIIB. Along with previous findings, this study helps provide a deeper understanding of the pathology landscape of this rare disease with high unmet medical need and serves as an important resource to the scientific community.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Mucopolysaccharidosis III Type of study: Prognostic_studies / Risk_factors_studies Limits: Adult / Animals / Child / Humans Language: En Journal: Sci Rep Year: 2023 Type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Mucopolysaccharidosis III Type of study: Prognostic_studies / Risk_factors_studies Limits: Adult / Animals / Child / Humans Language: En Journal: Sci Rep Year: 2023 Type: Article Affiliation country: United States